Collagen-based Filler for Trapeziometacarpal Osteoarthritis
Key facts
- Who runs it
- Azienda Ospedaliera Universitaria Integrata Verona
- Where
- Italy1 site in 1 countryChoose a country to see its sites
- Trial code
- Status
- Completed
- People taking part
- 64 people enrolled
- Started
- 1 Jan 2021
- Ended
- 1 Jan 2025
- Type of study
- Observational
- Treatments tested
- Intra-articular injection
- Record updated
- 18 March 2025
Who can take part
- Age
- 18 years to 99 years
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
Show the full registry criteria (9)Hide the full registry criteria
Who can take part
- patients with rhizarthrosis diagnosed on X-rays performed in the last year
- patients aged > 18 years
- enrollment in the study through informed consent
Who cannot take part
- patients with underlying rheumatological diseases
- patients affected by metabolic disorders (e.g. diabetes)
- patients under 18 years of age
- patients who have undergone cortisone and/or hyaluronic acid infiltrations in the last 6 months
- patients following trauma involving the ATM
- ongoing pregnancy
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Introduction. Trapeziometacarpal osteoarthritis (TMC OA) is a degenerative condition characterized by pain, stiffness, and reduced hand function, significantly impairing daily activities. Non-surgical management strategies include activity modifications, nonsteroidal anti-inflammatory drugs (NSAIDs), splinting, and corticosteroid injections. When conservative treatments fail, surgical options are considered. The Eaton-Littler classification stratifies TMC OA into four stages based on radiographic joint degeneration.
Read full original descriptionShow less
ChondroFiller Liquid®, a cell-free collagen scaffold composed of native type I collagen and chondrostimulating factors, facilitates cartilage regeneration by creating a protective environment for chondrocyte proliferation. It is indicated for treating cartilage lesions up to 3 cm². A prior study demonstrated its efficacy in alleviating pain, improving grip strength (Jamar test and pinch test), and enhancing Patient-Reported Outcome Measures (PROMs) using the Disabilities of the Arm, Shoulder, and Hand (DASH) score.
Aims. This study aims to extend the follow-up to 24 months to evaluate the long-term sustainability of clinical improvements following ChondroFiller Liquid® infiltration.
Materials and Methods. A total of 40 patients from the initial study were enrolled and categorized into two severity groups based on the Eaton-Littler classification. Clinical evaluations were conducted at 18 months post-infiltration (T1) using the Numeric Rating Scale (NRS) and DASH score. A subsequent assessment at 24 months (T2) included the Jamar test, pinch test, NRS, and DASH score. An additional cohort of 51 patients underwent infiltration with a mean follow-up of 14 months, including 9 patients previously treated in the preliminary study.
Treatments tested
- Intra-articular injection
Data and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- The Use of Collagen-based Filler for Trapeziometacarpal Osteoarthritis. Long-term Follow Up and Future Applications
- Publications
- Record updated
- 18 March 2025